Comparative open, randomized, cross-over bioequivalence study of two intravenous dexrazoxane formulations (Cardioxane® and ICRF-187) in patients with advanced breast cancer, treated with 5-fluorouracil-doxorubicin-cyclophosphamide (FDC)
Titel:
Comparative open, randomized, cross-over bioequivalence study of two intravenous dexrazoxane formulations (Cardioxane® and ICRF-187) in patients with advanced breast cancer, treated with 5-fluorouracil-doxorubicin-cyclophosphamide (FDC)
Auteur:
Rosing, H. Ten Bokkel Huinink, W. W. van Gijn, R. Rombouts, R. F. M. Bult, A. Beijnen, J. H.
Verschenen in:
European journal of drug metabolism and pharmacokinetics